In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases.
FCE 22101 is a new penem with broad antibacterial spectrum, excluding the pseudomonads, and has stability to many beta-lactamases. FCE 22101 and imipenem were very potent against the bacteria studied, including beta-lactamase producing strains, which can be isolated from patients with respiratory tract infections (MIC less than or equal to 8 mg/l). No strains were found to be resistant to FCE 22101. FCE 22101 was rapidly bactericidal and more stable to inactivation by beta-lactamases from Branhamella catarrhalis, Haemophilus influenzae, Enterobacter cloacae and Klebsiella pneumoniae than imipenem and ceftibuten. The other antibiotics tested varied in their activities against the respiratory tract pathogens.
Dornbusch
K
K
Department of Clinical Microbiology, Karolinska Hospital, Stockholm, Sweden.
Kronvall
G
G
Göransson
E
E
Mörtsell
E
E
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000201:enzymology; D015780:Carbapenems; D000077722:Ceftibuten; D002511:Cephalosporins / Q000494:pharmacology; D015378:Imipenem / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D012141:Respiratory Tract Infections / Q000382:microbiology*; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D002511:Cephalosporins; D015378:Imipenem; C040033:ritipenem; D001618:beta-Lactamases; D000077722:Ceftibuten